Business Wire

ReadSpeaker VoiceLab Powers Sonos Voice Control Custom Voice

17.5.2022 15:00:00 EEST | Business Wire | Press release

Share

ReadSpeaker, the most trusted, independent digital voice partner for global businesses, today announced that Sonos, the world’s leading sound experience company, has selected the ReadSpeaker VoiceLab to create a custom voice for Sonos Voice Control, the brand’s voice assistant. Sonos selected VoiceLab, ReadSpeaker’s custom voice production unit, because of the company’s proven experience and expertise in state-of-the-art, AI-driven text-to-speech.

Leading consumer brands are looking to develop their own voice assistants to provide consistently on-brand, personalized and engaged automated customer experiences. Those with a visionary strategy and commitment to consumer privacy, like Sonos, are understanding the broader importance of AI-driven digital voice in helping expand their business and meet consumer needs and expectations, even as they quickly evolve.

The ReadSpeaker VoiceLab managed the development process, including carrying out recordings with Giancarlo Esposito, processing the recorded data, training Deep Neural Networking (DNN) models on that data, and managing quality control, delivery, and all necessary quality assurance steps. Because of the technicality of the voice recordings required to build the custom voice, which requires speech to be delivered in an extremely consistent way that prioritizes precise articulation and style, ReadSpeaker’s VoiceLab experts worked closely with Esposito throughout every stage of the process.

A key challenge in the development of this custom voice was the need for it to comprehend and pronounce non-standard text content that is often found in the music industry. It was also critical that the assistant was able to read artists’ track or album information in numerous languages. The VoiceLab team worked closely with Sonos and Esposito to optimize the speech output for this massively broad domain.

Sonos Voice Control is an entirely new voice experience that delivers fast, accurate hands-free control of your music and your Sonos system with unmatched privacy. Designed with privacy at its core, Sonos Voice Control is the simplest way to control your music, offering complete command of your Sonos system using only your voice. Sonos Voice Control works on every voice-capable Sonos speaker, processing requests entirely on the device. No audio or transcript is sent to the cloud, stored, listened to or read by anyone. Available from June 1 in the US and later this year in France on all voice capable Sonos products, Sonos Voice Control is compatible with Sonos Radio, Apple Music, Amazon Music, Deezer, and Pandora at launch. More services and markets will follow.

“We selected ReadSpeaker to power the custom voice for Sonos Voice Control for a variety of reasons, not least of which was their ability to work closely with us from the development phase all the way through delivery,” said Joseph Dureau, Vice President, Voice Experience, at Sonos. “ReadSpeaker’s approach to custom voice is innovative and extremely thorough – which is exactly what we required for this project – and the company’s dedicated linguistic team has been a critical tool for us throughout this project.”

“As brands become increasingly aware that, much like a visual logo, a custom voice ensures consistently engaging, on-brand interactions across touchpoints, our VoiceLab is developing voices that speak to their brand persona and create unique experiences,” said Roy Lindemann, CMO and CCO EMEA, at ReadSpeaker. “With more consumers leveraging digital voice every day for everything from making purchases to choosing which playlist to listen to, having a custom branded voice is becoming table stakes for delivering a quality, personalized CX in real time. By partnering with Sonos, we are helping to bring yet another brand’s voice to life in an exciting, innovative way.”

Watch the SVC Custom Voice “behind the scenes” video here: https://www.youtube.com/watch?v=vwJ8Ub10arQ

For more information about the ReadSpeaker VoiceLab, visit www.readspeaker.ai/solutions/custom-text-to-speech-tts-voices/.

About ReadSpeaker:
ReadSpeaker is the most trusted independent digital voice partner for global brands, institutions, and organizations. With over 20 years’ experience, ReadSpeaker’s AI-powered text-to-speech solutions and expert assistance enhance the accessibility of digital content and enable more user-friendly and engaging interactions with technology. The company’s flexible cloud and on-premise solutions bring over 110 expressive, humanlike synthetic voices in more than 35 languages to any application or device. The company consistently maintains its uncompromising commitment to data privacy and has so far speech enabled over 10,000 voice applications worldwide.

ReadSpeaker’s digital voice design brand, readspeaker.ai, helps agencies, integrators, and developers to enhance CX and drive sales through consistently engaging, on-brand interactions across touchpoints. For more information, go to readspeaker.ai and follow the company on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ReadSpeaker:
Victoria Newell
V2 Communications for ReadSpeaker
readspeaker@v2comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye